Journal Article

DKFZ-2021-00733

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.

Aglago, E. K. ; Schalkwijk, C. G. ; Freisling, H. ; Fedirko, V. ; Hughes, D. J. ; Jiao, L. ; Dahm, C. C. ; Olsen, A. ; Tjønneland, A. ; Katzke, V.DKFZ* ; Johnson, T.DKFZ* ; Schulze, M. B. ; Aleksandrova, K. ; Masala, G. ; Sieri, S. ; Simeon, V. ; Tumino, R. ; Macciotta, A. ; Bueno-de-Mesquita, B. ; Skeie, G. ; Gram, I. T. ; Sandanger, T. ; Jakszyn, P. ; Sánchez, M.-J. ; Amiano, P. ; Colorado-Yohar, S. M. ; Gurrea, A. B. ; Perez-Cornago, A. ; Mayén, A.-L. ; Weiderpass, E. ; Gunter, M. J. ; Heath, A. K. ; Jenab, M.

2021
Oxford Univ. Press Oxford

This record in other databases:  

Please use a persistent id in citations: doi:10.1093/carcin/bgab026

Abstract: Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino-acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case-control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs: N ε-(carboxy-methyl)lysine (CML), N ε-(carboxy-ethyl)lysine (CEL) and N δ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were measured by ultra-performance liquid chromatography tandem mass-spectrometry in baseline samples collected from 1,378 incident primary colorectal cancer cases and 1,378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression for colorectal cancer risk associated with CML, CEL, MG-H1, total AGEs, and [CEL+MG-H1: CML] and [CEL:MG-H1] ratios. Inverse colorectal cancer risk associations were observed for CML (OR comparing highest to lowest quintile, ORQ5vs.Q1=0.40, 95%CI:0.27-0.59), MG-H1 (ORQ5vs.Q1=0.73, 95%CI:0.53 - 1.00) and total AGEs (OR Q5vs.Q1=0.52, 95%CI:0.37 - 0.73) whereas no association was observed for CEL. A higher [CEL+MG-H1: CML] ratio was associated with colorectal cancer risk (ORQ5vs.Q1=1.91, 95%CI:1.31-2.79). The associations observed did not differ by sex, or by tumour anatomical subsite. Although individual AGEs concentrations appear to be inversely associated with colorectal cancer risk, a higher ratio of methylglyoxal-derived AGEs versus those derived from glyoxal (calculated by [CEL+MG-H1: CML] ratio) showed a strong positive risk association. Further insight on the metabolism of AGEs and their dicarbonyls precursors, and their roles in colorectal cancer development is needed.

Keyword(s): Advanced glycation end-product ; colorectal cancer ; glycotoxin

Note: 2021 May 28;42(5):705-713

---

Contributing Institute(s):

1. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2021

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---